-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $151.00
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $151.00
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $128.25.
A number of research firms have recently commented on NVAX. JPMorgan Chase & Co. lowered shares of Novavax from a "neutral" rating to an "underweight" rating and cut their price objective for the company from $132.00 to $27.00 in a research report on Thursday. Cowen reduced their target price on Novavax to $110.00 in a research note on Monday, August 15th. B. Riley reduced their target price on Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Cowen reduced their target price on Novavax from $150.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th.
Get Novavax alerts:Novavax Stock Performance
NVAX opened at $21.00 on Thursday. The firm has a market cap of $1.64 billion, a P/E ratio of -1.08, a PEG ratio of 0.10 and a beta of 1.65. The firm has a 50-day moving average of $41.22 and a 200 day moving average of $52.06. Novavax has a fifty-two week low of $20.46 and a fifty-two week high of $257.30.
Novavax (NASDAQ:NVAX – Get Rating) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by ($12.04). The business had revenue of $186.00 million for the quarter, compared to the consensus estimate of $1.02 billion. Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. Novavax's revenue for the quarter was down 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($4.75) EPS. Equities research analysts predict that Novavax will post 6.09 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of NVAX. Mascoma Wealth Management LLC purchased a new position in Novavax during the 2nd quarter valued at approximately $27,000. San Luis Wealth Advisors LLC purchased a new position in Novavax during the 1st quarter worth approximately $29,000. Focused Wealth Management Inc purchased a new position in shares of Novavax during the 1st quarter valued at approximately $45,000. Exchange Traded Concepts LLC purchased a new position in shares of Novavax during the 2nd quarter valued at approximately $47,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novavax in the 1st quarter worth $53,000. Institutional investors own 42.63% of the company's stock.
Novavax Company Profile
(Get Rating)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Featured Stories
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) have received a consensus rating of "Hold" from the nine research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $128.25.
据Marketbeat报道,诺华公司(纳斯达克代码:NVAX-GET Rating)的股票得到了九家研究公司的一致评级,即持有。两名分析师对该股的评级为卖出建议,一名分析师给出了持有建议,三名分析师给出了买入建议。过去一年对该股进行评级的分析师的平均12个月目标价为128.25美元。
A number of research firms have recently commented on NVAX. JPMorgan Chase & Co. lowered shares of Novavax from a "neutral" rating to an "underweight" rating and cut their price objective for the company from $132.00 to $27.00 in a research report on Thursday. Cowen reduced their target price on Novavax to $110.00 in a research note on Monday, August 15th. B. Riley reduced their target price on Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Cowen reduced their target price on Novavax from $150.00 to $110.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 9th. Finally, Cantor Fitzgerald increased their target price on Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th.
一些研究公司最近对NVAX发表了评论。摩根大通在周四的一份研究报告中将诺华的股票评级从中性下调至减持,并将该公司的目标价从132.00美元下调至27美元。考恩在8月15日星期一的一份研究报告中将诺华的目标价下调至110.00美元。B.莱利在7月22日星期五的一份研究报告中将诺华公司的目标价从181.00美元下调至171.00美元。考恩在8月9日周二的一份研究报告中将诺华铂的目标价从150.00美元下调至110.00美元,并对该股设定了“跑赢大盘”的评级。最后,坎托·菲茨杰拉德在6月8日星期三的一份研究报告中将诺华公司的目标价从146.00美元上调至168.00美元。
Novavax Stock Performance
Novavax股票表现
NVAX opened at $21.00 on Thursday. The firm has a market cap of $1.64 billion, a P/E ratio of -1.08, a PEG ratio of 0.10 and a beta of 1.65. The firm has a 50-day moving average of $41.22 and a 200 day moving average of $52.06. Novavax has a fifty-two week low of $20.46 and a fifty-two week high of $257.30.
NVAX周四开盘报21.00美元。该公司的市值为16.4亿美元,市盈率为-1.08,聚乙二醇率为0.10,贝塔系数为1.65。该公司的50日移动均线切入位在41.22美元,200日移动均线切入位在52.06美元。Novavax的52周低点为20.46美元,52周高位为257.30美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of institutional investors have recently bought and sold shares of NVAX. Mascoma Wealth Management LLC purchased a new position in Novavax during the 2nd quarter valued at approximately $27,000. San Luis Wealth Advisors LLC purchased a new position in Novavax during the 1st quarter worth approximately $29,000. Focused Wealth Management Inc purchased a new position in shares of Novavax during the 1st quarter valued at approximately $45,000. Exchange Traded Concepts LLC purchased a new position in shares of Novavax during the 2nd quarter valued at approximately $47,000. Finally, Dixon Hughes Goodman Wealth Advisors LLC purchased a new stake in Novavax in the 1st quarter worth $53,000. Institutional investors own 42.63% of the company's stock.
多家机构投资者最近买卖了NVAX的股票。Mascoma Wealth Management LLC在第二季度购买了Novavax的一个新头寸,价值约为2.7万美元。San Luis Wealth Advisors LLC在第一季度购买了Novavax的一个新头寸,价值约2.9万美元。Focus Wealth Management Inc.在第一季度购买了新的Novavax股票头寸,价值约4.5万美元。交易所交易的概念公司在第二季度购买了新的Novavax股票头寸,价值约4.7万美元。最后,Dixon Hughes Goodman Wealth Advisors LLC在第一季度购买了Novavax价值53,000美元的新股份。机构投资者持有该公司42.63%的股份。
Novavax Company Profile
Novavax公司简介
(Get Rating)
(获取评级)
Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
Novavax,Inc.是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重的传染病和满足卫生需求。该公司的候选疫苗包括冠状病毒候选疫苗NVX-CoV2373,它正在进行两项第三阶段试验、一项IIb阶段试验和一项I/II阶段试验;NanoFlu,一种处于第三阶段临床试验的季节性四价流感疫苗候选产品;以及ResVax,一种呼吸道合胞病毒(RSV)融合(F)蛋白质纳米颗粒疫苗候选产品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Novavax (NVAX)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- 免费获取StockNews.com关于Novavax的研究报告(NVAX)
- 华尔街对Datadog的热情会带来巨大的收益吗?
- MarketBeat:回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性?
- 好市多盈利后价格疲软是买入的好时机吗?
- 需要关注的2只半导体类股走势逆转
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受Novavax Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Novavax和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧